Innovation Grants have been created to support innovative, creative problem solving in cancer research. As competition for grant funding increases, peer review panels become more conservative and risk averse, emphasizing feasibility more than innovation. The goal of this CCSRI grant program is to support unconventional concepts, approaches or methodologies to address problems in cancer research. Innovation projects will include elements of creativity, curiosity, investigation, exploration and opportunity. Successful projects may be based on “high risk” ideas, but will have the potential for “high reward” (i.e. to significantly impact our understanding of cancer and generate new approaches to combat the disease by introducing novel ideas into use or practice).

It is hoped that this grant program will accelerate the introduction of innovation into the entire cancer research system and contribute to the scientific idea pipeline. Significant findings from investigators funded by Innovation Grants may be developed further through CCSRI "Innovation to Impact" Grants or operating grants offered by other agencies.

The Genomic Applications Partnership Program (GAPP) represents a key element in Genome Canada’s strategic plan towards funding downstream research and development (R&D) projects that are driven by challenges and opportunities facing users of genomics based technologies. For the purpose of this program, “Users” include the various stakeholders that have an interest in “pulling” technologies and other results of genomics research from academia to market and application, including industry, government, not-for-profits, and other organizations.

The GAPP aims to:

• Promote the application of genomics-derived solutions to address key sector challenges or opportunities facing Users – User “pull”;
• Promote commercialization of genomics technologies by enabling the transfer of genomics-derived solutions from Academia to Users as well as de-risking and incentivizing follow-on investment from public and private partners;
• Increase the socio-economic impact of genomics research by accelerating its translation to application or market; and,
• Create and foster a more productive interface between Academia and Users.

Competition Timelines

Round 7:

The Mitacs Globalink Research Internship (GRI) is now accepting faculty submissions for Summer 2017. GRI pairs faculty in Canada with international undergrads for 12-week research projects from May to September.

• All disciplines are eligible
• Top-ranked senior undergrads travel from Australia, Brazil, China, France, Germany, India, Mexico, Tunisia, and Saudi Arabia
• Faculty can submit multiple projects and re-submit projects from previous years

Submit projects by June 16, 2016, at 5 p.m. PDT.

Questions? Visit our website or contact globalink@mitacs.ca. 

The FY16 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Autism Research Program (ARP) to support innovative, high-impact autism spectrum disorder research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY16 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

http://cdmrp.army.mil/funding/bcrp.shtml

Clinical Trial Award – Preapplication due 6/22/16

Investigators at or above the level of Associate Professor (or equivalent)

• Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
• Preliminary data relevant to the proposed project are required.
• Pre-application is required; application submission is by invitation only.

• Behavioral, cognitive, and other non-pharmacological therapies
• Pharmacological treatments in autism or well-defined subgroups of autism
• Dissemination/Implementation of efficacious behavioral interventions (including measures of fidelity and outcomes)
• Therapies to alleviate conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, aggression, depression, anxiety, attention deficit)

• Maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)
• Maximum period of performance is 4 years

Idea Development Award – Preapplication is due 6/22/16

Investigators at all academic levels (or equivalent)

• Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
• Preliminary data are required.
• Multiple Principal Investigator (PI) Option: Up to three investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
• Pre-application is required; application submission is by invitation only.

• Assessment of novel therapeutics using valid preclinical models
• Environmental risk factors
• Mechanisms of heterogeneous clinical expression of ASD
• Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, aggression, depression, anxiety, attention deficit)
• Factors promoting success in key transitions to independence for individuals living with ASD

• Maximum funding for the entire period of performance is $377,000 in direct costs (plus indirect costs)
• For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $377,000 in direct costs (plus indirect costs)
• Maximum period of performance is 3 years

The FY16 Defense Appropriations Act provides $50 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/ Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY16 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY16 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted. 

The FY16 PRCRP Topic Areas are listed below:

*As derived from the National Cancer Institute Dictionary of Cancer terms¹: Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this topic area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

The FY16 PRCRP Military Relevance Focus Areas are listed below:

To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY16 PRCRP seeks to support studies that are responsive to the Military Relevance Focus Areas listed below:

• Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens)
• Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, Veterans, and their beneficiaries

Applications that address exposures, conditions, or circumstances that are unique to the military, or disproportionately represented in a military beneficiary population, are the highest priority, though any applications that address the above focus areas will be considered.

http://cdmrp.army.mil/funding/prcrp.shtml

Career Development Award- Preproposal due 6/8/16

Principal Investigator (PI): Independent early-career investigator within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

Designated Mentor: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research. 

·         Preproposal is required; application submission is by invitation only.

·         Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher

·         Must address at least one of the FY16 PRCRP Topic Areas

·         Strongly encouraged to address at least one of the FY16 PRCRP Military Relevance Focus Areas

·         Preliminary data not required

Clinical trials are not allowed

·       Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 3 years

Idea Award with Special Focus – Preproposal due 6/8/16

Independent investigator with a faculty-level appointment (or equivalent).

·         Preproposal is required; application submission is by invitation only.

·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to Service members, their families, and other military beneficiaries

·         Emphasis on innovation and military relevance/impact

·         Must address at least one of the FY16 PRCRP Topic Areas

·         Must address at least one of the FY16 PRCRP Military Relevance Focus Areas

·         Preliminary data not required

Clinical trials are not allowed

·       Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 2 years

Translational Team Science Award – Preproposal due 6/8/16

At least two and up to three PIs must partner in one overarching correlative or translational research study.

At least one of the PIs is encouraged to be a military or Department of Veterans Affairs investigator.

·         Preproposal is required; application submission is by invitation only.

·         Supports translational correlative studies associated with an ongoing or completed clinical trial and/or translational study that can lead to a future clinical trial or clinical application in cancer research that is relevant to Service members, their families, and other military beneficiaries

·         Not intended to support high throughput screenings, sequencing, etc.

·         Must address at least one of the FY16 PRCRP Topic Areas

·         Must address at least one of the FY16 PRCRP Military Relevance Focus Areas

·         Preliminary data is required

Clinical trials are not allowed

·       Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 3 years

A pre-application is required and must be submitted through the CDMRP electronic Biomedical Research Application Portal (eBRAP) website (https://eBRAP.org) prior to the pre-application deadline.  All applications must conform to the final Program Announcement(s) and General Application Instructions available for electronic downloading from the Grants.gov website.  Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Requests for email notification of the Program Announcement(s) release may be sent to help@eBRAP.org.  Email notifications of funding opportunities are sent as a courtesy and should not be used as a sole source of notification; applicants should monitor Grants.gov for official postings of funding opportunities.

For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

Applications to the Fiscal Year 2016 (FY16) Multiple Sclerosis Research Program (MSRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA RDA Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The MSRP, established in FY09, is dedicated to supporting pioneering concepts and high-impact research that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of multiple sclerosis (MS) to ultimately lessen its personal and societal impact. Appropriations for the MSRP from FY09 through FY15 totaled $33.1 million (M). The FY16 appropriation is $6M.

Funding opportunities under this program:

• Pilot Clinical Trial Award
• Investigator Initiated Research Award
• Exploration - Hypothesis Development Award

The aim of the call is to support research which will improve the understanding of how different approaches to welfare secure the quality of life, especially of older people. A better understanding of these differences will help policymakers to identify potential ways of meeting needs, as models evolve in response to changing demographic pressures and circumstances.

Relevant Research Areas

Proposals must address one or more of these three research topics:

• Understanding wellbeing: how appropriate are current measures of wellbeing across the changing life course?
• Intergenerational relationships: how can welfare models distribute resources, rights and responsibilities in fair and sustainable ways?
• Welfare models: How can welfare models secure the health and wellbeing for older people confronted to caring needs, subject to frailty and nearing the end of life?

For more information, please consult the Joint Programming Initiative “More Years, Better Lives” (JPI-MYBL) website.

Call 2016: Welfare, Wellbeing and Demographic Change: Understanding Welfare Models

Application Deadline: April 12, 2016

Anticipated Notice of Decision: November 1, 2016

Funding Start Date: February 1, 2017

Funds Available: The total amount available for this funding opportunity is $1,500,000, enough to fund approximately up to 5 grants.

The maximum amount per grant is $300,000 - up to $100,000 per year over 3 years.

Of this $1,500,000:

• $1,000,000 is available to fund the Canadian component of applications relevant to the mandate of CIHR.
• $500,000 is available to fund the Canadian component of applications relevant to the mandate of the Social Sciences and Humanities Research Council (SSHRC).

Joint Programming is a new approach to foster collaboration and coordination in R&D in Europe and Canada and is a member-states driven activity. JPI-MYBL seeks to enhance coordination and collaboration between European and Canadian research programs related to demographic change.

Welfare models are deeply embedded in historical, cultural and economic contexts, and there are rarely simple transferable lessons. However, comparative studies can help us to understand the implications, strengths and weaknesses of particular institutional configurations, and how well they meet the needs of particular population groups. A better understanding of these differences can help policymakers identify potential ways of meeting needs, as their own models evolve in response to changing pressures and circumstances.

This is an international funding opportunity: Each proposal must involve a minimum of three eligible applicants from at least three different countries participating in the call. The maximum number of eligible participants in a project consortium is seven. The consortium should be reasonably balanced, not more than two eligible applicants per country/funding organization are allowed.

Participating countries: Austria, Belgium, Canada, Finland, France, Israel, Italy, Norway, Portugal, Spain, The Netherlands

Read more about this opportunity at JPI MYBL

The objective of this funding opportunity is  to bring together technologies and services to create Information and Communication Technology (ICT) based solutions with a clear route to market that will enable the wellbeing of people with dementia and their communities (family, caregivers, neighbourhood, service providers, care system, etc.).

For more information, please consult the Active and Assisted Living website.

Active and Assisted Living (AAL) Programme Call 2016

Living Well with Dementia

Application Deadline: May 26, 2016           

Anticipated Notice of Decision: November 30, 2016

Funding Start Date: October 1, 2016

Funds Available: The total Canadian amount available for this funding opportunity is $706,000 (CAD) enough to fund approximately two (2) grants. This amount may increase if additional funding partners participate.

• CIHR will contribute up to $117,666 (CAD) per year for 1 grant for a maximum of three years.
• AGE-WELL NCE will contribute up to $117,666 (CAD) per year for 1 grant for a maximum of three years.

The focus of the 2016 Call Challenge of the AAL Programme is to fund information and communication technology (ICT) based innovative, transnational and multi-disciplinary collaborative projects with a clear route to market that support people with dementia and their caregivers to live in dignity and provide satisfaction through all stages of dementia.

Eligibility: Consortium composition of at least 3 independent eligible organizations (legal entities), from at least 3 different AAL Partner States participating in the Call for Proposals; English as the language of the proposal

Partner countries: Austria, Belgium, Canada, Cyprus, Denmark,  France, Hungary, Ireland, Israel, Italy, Luxembourg, Netherlands, Norway, Poland, Romania, Portugal, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

CIHR Canadian Eligibility Requirements

A Partner Matching Tool is available to connect with other partner states. 
 

Information day: An informational webcast will be available online within a few days of March 8, 2016.

Info Day Webcast

AAL

The Active and Assisted Living (AAL) Programme is a common funding activity of member states of the AAL Association, with the financial support of the European Commission, based on article 185 of the Treaty on the Functioning of the European Union. The AAL Programme calls are complementary to the Horizon 2020 calls related to Active and Healthy Ageing under Societal Challenge 1.

The AAL Call 2016 is part of the AAL Programme that was approved in May 2014 by the European Parliament and the Council of the European Union. As part of the work-programme, the AAL is launching a Call for Proposals: “Living well with dementia: Providing integrated solutions based on information and communication technology to support the wellbeing of people living with dementia and their communities.”

Grand Challenges China: New Interventions for Global Health.  This challenge focuses on calls for innovative concepts for safe, effective, affordable and widely utilized interventions, such as vaccines and therapeutics, with the potential to protect against the acquisition, progression or transmission of infectious diseases that disproportionately affect the world’s poorest.  This call is in partnership with the National Natural Science Foundation of China and requires substantive collaborations between China-based investigators and those based outside of China.

Application deadline is March 15, 2016, 8:00 am Beijing time (March 14, 2016, 5pm Seattle time). For a detailed description of this challenge, please visit the Grand Challenges site.

This Knowledge to Action Grant has been created to encourage ideas that will close the gap between what is known from research and what is done with that knowledge in the health care community and public health practice. These grants are intended to provide funding for research projects that build on existing cancer research findings and aim to improve outcomes and experiences through knowledge translation (KT) for people and populations at risk, patients, their families and communities across the cancer trajectory e.g., to assist knowledge users (researchers, practitioners, policy makers, CCS program delivery staff and/or volunteers) in their awareness of knowledge or innovations and facilitating their use in health or healthcare system improvement. The grant should incorporate the principles of knowledge translation including knowledge synthesis, dissemination, exchange and/or ethically sound application of knowledge to improve health and the health system.